Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2026)
Bicycle Therapeutics (BCYC) reported Cash from Investing Activities of -$713000.0 for Q1 2026, down 18.05% on a YoY basis from -$870004.0 in Q1 2025, and down 24.22% quarter-over-quarter from -$574000.0 in Q4 2025.
Bicycle Therapeutics (BCYC) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics has reported Cash from Investing Activities for 9 years, with the latest figure at -$713000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 18.05% year-over-year to -$713000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 34.59% YoY), and the FY2025 full-year result was -$2.4 million, down 90.28% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$713000.0, down from -$574000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$12000.0 in Q1 2024, with the low at -$9.8 million in Q2 2022.
- Historically, Cash from Investing Activities has averaged -$1.5 million across 5 years, with a median of -$574000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 5630.41% — and 2024, when it jumped 99.43%.
- Bicycle Therapeutics' Cash from Investing Activities stood at -$1.4 million in 2022, then jumped by 96.48% to -$51000.0 in 2023, then plunged by 621.57% to -$368000.0 in 2024, then sank by 55.98% to -$574000.0 in 2025, then dropped by 24.22% to -$713000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$713000.0 (Q1 2026), -$574000.0 (Q4 2025), and -$674000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -713,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -713,000.00 |
| Mar 31, 2026 | -713,000.00 |
| Dec 31, 2025 | -574,000.00 |
| Dec 31, 2025 | -574,000.00 |
| Sep 30, 2025 | -674,000.00 |
| Sep 30, 2025 | -674,000.00 |
| Jun 30, 2025 | -498,000.00 |
| Jun 30, 2025 | -498,000.00 |
| Mar 31, 2025 | -604,000.00 |
| Mar 31, 2025 | -604,000.00 |
| Dec 31, 2024 | -368,000.00 |
| Dec 31, 2024 | -368,000.00 |
| Sep 30, 2024 | -435,000.00 |
| Sep 30, 2024 | -435,000.00 |
| Jun 30, 2024 | -420,000.00 |
| Jun 30, 2024 | -420,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | -51,000.00 |
| Dec 31, 2023 | -51,000.00 |